A Real Time Monitoring System for IOP in Glaucoma

青光眼眼压实时监测系统

• 批准号: 6631101
• 负责人: Doug J Jackson
• 金额: $ 25.07万
• 依托单位: ASSENTI, LLC
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-05-01 至 2005-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6631101
• 关键词: assistive device /technology; bioengineering /biomedical engineering; biomedical equipment development; glaucoma; intraocular pressure; laboratory rabbit; microprocessor /microchip; miniature biomedical equipment; optic nerve disorder; patient monitoring device; telemetry

DESCRIPTION (provided by applicant): Assenti's enclosed NEI / SBIR proposal is intended to provide continuous, non-invasive 24 hour monitoring of Intra-Ocular Pressure (lOP) in patients with optic nerve damage from glaucoma. The project can be viewed as "assistive technology for prevention of blindness". Elevated lOP is thought to be the most important risk factor for the initiation and progression of glaucoma. The current therapeutic management of glaucoma, based on several clinical studies, aims to halt disease progression by reducing lOP to clinically acceptable levels using medical, laser or surgical treatments. The Ocular Hypertension Treatment Study (OHTS) has recently identified elevated lOP as an important predictor for the onset of glaucoma [9]. The Advanced Glaucoma Intervention Study demonstrated a protective role for low lOP in visual field deterioration detected in glaucomatous patients [10]. Even in NPG disease progression has been shown to be markedly reduced by the traditional intervention of lOP reduction [11,12]. Experimental studies using animal models of glaucoma support the clinical observations that lOP initiated factors are important for glaucomatous degeneration of the optic nerve. Collaborative research teams from the University of Louisville's Speed School of Engineering and the Department of Ophthalmology & Visual Sciences along with key industry partners have combined to form a corporation named Assenti LLC. Assenti will construct an integrated circuit (IC) pressure sensor with onboard telemetry that will be placed within the anterior chamber of the glaucomatous eye to record Lop between 10 and 40 mm Hg continuously over 24 hours. The telemetric circuit will be developed to provide power to the sensor IC as well as receive data from the sensor IC without requiring batteries or wires. The primary coil that provides power and receives data from the IC will be housed on spectacle frames, which can be worn by the subject. It is envisioned that all patients with established glaucoma in whom treatment has been initiated, either medical or surgical, would be candidates for the device. The three specific aims and for this potentially revolutionary treatment of glaucoma are as follows: 1. Fabricate 2 ultra-miniature MEMS pressure sensors based on a piezoresistive and capacitance designs. 2. Development of the telemetry circuitry for power and data communication. 3. Test the MEMS pressure sensors and telemetry circuitry under both in vitro and in vivo conditions.

描述（由申请人提供）：Assenti 随附的 NEI / SBIR 提案旨在为因青光眼导致视神经损伤的患者提供连续、非侵入性的 24 小时眼内压 (IOP) 监测。该项目可以被视为“防盲辅助技术”。 IOP升高被认为是青光眼发生和进展的最重要的危险因素。目前青光眼的治疗管理基于多项临床研究，旨在通过将 IOP 降低至临床水平来阻止疾病进展。 使用医疗、激光或手术治疗的可接受水平。高眼压治疗研究 (OHTS) 最近发现 IOP 升高是青光眼发病的重要预测因素 [9]。高级青光眼干预研究证明，低 IOP 对青光眼患者视野恶化具有保护作用 [10]。即使在 NPG 中，通过减少 IOP 的传统干预措施也可以显着减少疾病进展 [11,12]。使用青光眼动物模型的实验研究支持了 IOP 引发因素对于视神经青光眼变性很重要的临床观察结果。 来自路易斯维尔大学 Speed 工程学院和眼科与视觉科学系的合作研究团队与主要行业合作伙伴联合成立了一家名为 Assenti LLC 的公司。 Assenti 将构建一个带有机载遥测功能的集成电路 (IC) 压力传感器，将其放置在青光眼眼的前房内，以在 24 小时内连续记录 10 至 40 毫米汞柱之间的 Lop。遥测电路将被开发为传感器 IC 提供电源并从传感器 IC 接收数据，而无需电池或电线。提供电源并从 IC 接收数据的初级线圈将安装在眼镜架上，受试者可以佩戴眼镜架。预计所有已确诊青光眼的患者接受治疗 已经启动，无论是医疗还是外科手术，都将成为该设备的候选者。这种潜在的革命性青光眼治疗的三个具体目标如下： 1. 制作2个基于压阻和电容设计的超微型MEMS压力传感器。 2. 电力和数据通信遥测电路的开发。 3. 在体外和体内条件下测试 MEMS 压力传感器和遥测电路。